Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 31Burkitt Lymphoma 12Recurrence 11Lung Neoplasms 11Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell 4Leukemia 4Wilms Tumor 3Sarcoma, Ewing 3Plasmablastic Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Immunoblastic Lymphadenopathy 3Ganglioneuroblastoma 3Waldenstrom Macroglobulinemia 2

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Etoposide × 90 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡